James Alan Tumlin MD
Acute Renal Failure, Critical Care, Glomerular Disease, Interventional Nephrology
Professor, Clinical Education-Chattanooga, University of Tennessee Health Science Center College of Medicine
Join to View Full Profile
595 Hurricane Shoals Road NorthwestSuite 100Lawrenceville, GA 30046
Phone+1 404-645-7150
Dr. Tumlin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Emory University School of MedicineNephrology, 1989 - 1991- Emory University School of MedicineInternal Medicine, 1986 - 1989
University of South Florida College of MedicineClass of 1986
Certifications & Licensure
GA State Medical License 1987 - 2025
TN State Medical License 2008 - 2025
NC State Medical License 2005 - 2010
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Nephrology
Clinical Trials
- Comparative and Efficacy Study of ACTHar Gel Alone or in Combination With Tacrolimus in Fibrillary Glomerulopathy Start of enrollment: 2019 Jan 12
Roles: Contact, Study Director, Principal Investigator
- Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy Start of enrollment: 2018 Oct 01
Roles: Contact, Sponsor-Investigator
- A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease Start of enrollment: 2022 Dec 26
Roles: Principal Investigator
Publications & Presentations
PubMed
- 1 citationsVadadustat Three Times Weekly in Patients With Anemia Due to Dialysis-Dependent CKD.Hakan R Toka, Marializa Bernardo, Steven K Burke, Wenli Luo, Roberto Manllo-Karim
American Journal of Kidney Diseases. 2025-04-01 - 3 citationsEffects of dialysate potassium concentration of 3.0 mmol/l with sodium zirconium cyclosilicate on dialysis-free days versus dialysate potassium concentration of 2.0 mm...David M Charytan, Wolfgang C Winkelmayer, Christopher B Granger, John P Middleton, Charles A Herzog
Kidney International. 2025-01-01 - Targeting the Type I Interferon Pathway in Glomerular Kidney Disease: Rationale and Therapeutic Opportunities.James Tumlin, Brad Rovin, Hans-Joachim Anders, Eduardo F Mysler, David R W Jayne
Kidney International Reports. 2025-01-01
Press Mentions
Faster, More Frequent Proteinuria Reduction with Sparsentan in FSGSApril 14th, 2025- Complement Inhibitor Shows Promise for Rare Kidney DisorderOctober 28th, 2024
Grant Support
- Enhanced renal dialysis membrane performance using lipocalin modified substratesHIBAR MICROSCIENCES, LLC2023–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
